2012 Annual Meeting | Myelopathies

Date Wednesday 04/25/12

Time 02:00 PM - 06:00 PM Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type PM Half-Day Course

Director(s) Dean M. Wingerchuk, MD, FAAN

Topic(s)

Learning Objectives Participants should be familiar with the wide spectrum of myelopathies and myeloneuropathies and develop a practical and systematic approach toward the investigation and management of these disorders. Participants should be aware of the recent advances related to spinal dural arteriovenous fistulas, neuromyelitis optica and other autoimmune disorders, copper deficiency, and other metabolic, toxic, and genetic disorders.

CME Available No CME available

Core Competencies Patient Care & Procedural Skills, Medical Knowledge, Practice-based Learning and Improvement

Recommended Audience Trainee, General Neurologist, Specialist Neurologist, Non-neurologist

Teaching Styles Case-based, Didactic, Interactive, Audience Participation

Program Evaluations

Event Timeline
02:00 PM - 02:40 PM		Spinal Cord Syndromes and Vascular Myelopathy Jose Biller, MD, FACP, FAHA, FAAN
02:40 PM - 03:20 PM		Approach to Myeloneuropathy Syndromes Brent P. Goodman, MD
03:20 PM - 04:00 PM		Infectious and Autoimmune Myelopathies Dean M. Wingerchuk, MD, FAAN
04:00 PM - 04:15 PM		Break
04:15 PM - 05:00 PM		Metabolic and Hereditary Myelopathies Neeraj Kumar, MD
05:00 PM - 06:00 PM		Discussion and Case Presentations

Faculty Disclosures
Dean M. Wingerchuk, MD, FAAN	Dr. Wingerchuk has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Imcyse. Dr. Wingerchuk has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck. Dr. Wingerchuk has received personal compensation in the range of $500-$4,999 for serving as a Consultant for TTY Biopharm. Dr. Wingerchuk has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Reistone Biopharm. Dr. Wingerchuk has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Horizon Therapeutics. Dr. Wingerchuk has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech. Dr. Wingerchuk has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Wingerchuk has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Wingerchuk has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Bristol Meyer Squibb. Dr. Wingerchuk has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB Pharma. Dr. Wingerchuk has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for AstraZeneca. Dr. Wingerchuk has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Wingerchuk has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Abcuro. Dr. Wingerchuk has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Wolters Kluwers.
Jose Biller, MD, FACP, FAHA, FAAN	Dr. Biller has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Wolters Kluwer. Dr. Biller has received publishing royalties from a publication relating to health care.
Neeraj Kumar, MD	Dr. Kumar has nothing to disclose.
Brent P. Goodman, MD	Dr. Goodman has nothing to disclose.

��ɫ��

��ɫ��